Neuropathix, Inc. is a biopharmaceutical company founded by Dean Petkanas and Thoma Kikis, headquartered in Doylestown, Pennsylvania. The company is dedicated to the research and development of next-generation therapeutics focused on pain management and neuroprotection. Neuropathix aims to address significant unmet medical needs by targeting inflammation through its innovative drug pipeline. Their products and services are designed to provide breakthrough treatments for patients suffering from chronic pain and neurodegenerative conditions.
Notable figures associated with Neuropathix include its founders, Dean Petkanas and Thoma Kikis. The company has achieved significant milestones, including securing patents (US 9611213, US 10004722) and receiving grant awards from the NIH-NINDS. Neuropathix's lead drug candidate, KLS-13019, has shown promising preclinical results, positioning the company as a key player in the biopharmaceutical industry. Their impact is marked by their commitment to advancing pain management therapies and contributing to the broader field of neuroprotective treatments.
